Form 8-K - Current report:
SEC Accession No. 0001420720-23-000004
Filing Date
2023-01-25
Accepted
2023-01-25 16:00:51
Documents
15
Period of Report
2023-01-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20230120x8k.htm   iXBRL 8-K 45358
2 EX-10.2 ibio-20230120xex10d2.htm EX-10.2 38143
3 GRAPHIC ibio-20230120xex10d2001.jpg GRAPHIC 4681
  Complete submission text file 0001420720-23-000004.txt   210911

Data Files

Seq Description Document Type Size
4 EX-101.SCH ibio-20230120.xsd EX-101.SCH 4009
5 EX-101.DEF ibio-20230120_def.xml EX-101.DEF 3279
6 EX-101.LAB ibio-20230120_lab.xml EX-101.LAB 11412
7 EX-101.PRE ibio-20230120_pre.xml EX-101.PRE 8543
9 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20230120x8k_htm.xml XML 3867
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 23552485
SIC: 2834 Pharmaceutical Preparations